This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
TMBIM1 / Protein lifeguard 3 · IHC design guide
Design Immunohistochemistry for TMBIM1
Plan paraffin-section TMBIM1 IHC using an IHC-validated antibody and cytoplasmic tissue staining as the starting pattern (HPA tissue IHC). This guide covers fixation consistency, chromogenic detection, and interpretation in light of its lysosome and endosome membrane annotation (UniProt).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
TMBIM1 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Cytoplasmic tissue staining (HPA tissue IHC); lysosome and endosome membranes (UniProt) | |
| Staining pattern | Cytoplasmic staining in most tissues (HPA tissue IHC) | |
| Antigen retrieval | EDTA pH 8.0 HIER, heat-mediated (datasheet A10501-3) | |
| Positive control | Appendix+4 more · see all | |
| Negative control | None in HPA (detected in all 45 tissues); use no-primary + isotype controls |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across sections (standard IHC practice; not target-specific) | |
| Caveat | Antibody staining and RNA show low consistency (HPA tissue IHC) | |
| Regulation | Expression regulation is not annotated (UniProt) | |
| Isoform / epitope | No isoforms or cleavage annotated; epitope side may affect access (UniProt) |
Section 1
Recommended TMBIM1 IHC & IF Protocols
Compare the catalog antibody’s IHC-P protocol (datasheet A10501-3) with 4 published TMBIM1 IHC protocols (PMC12702014; PMC12842013; PMC8920937; PMC12923484).
| Sample | Paraffin-embedded human gastric cancer tissue; fixative not specified (datasheet A10501-3) |
| Fixation | Image fixative and duration unreported (datasheet A10501-3); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: EDTA pH 8.0 (datasheet A10501-3); 20 min, 95–100 °C (standard) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% goat serum (datasheet A10501-3) |
| Primary antibody | Rabbit anti-TMBIM1, 2μg/ml (datasheet A10501-3) |
| Primary incubation | Overnight at 4 °C (datasheet A10501-3) |
| Detection | Streptavidin-biotin complex (SABC), DAB chromogen (datasheet A10501-3) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | TMBIM1-positive staining in lymphoid tissue of appendix (HPA tissue IHC: High). HPA tissue profile: Cytoplasmic expression in most tissues. No signal in the no-primary control. |
💡Decision noteStart with heat-mediated EDTA at pH 8.0 for the catalog antibody (datasheet A10501-3). Use each paper’s retrieval conditions when reproducing its protocol (PMC8920937; PMC12923484).
Section 2
What Is the Expected TMBIM1 Staining Pattern?
TMBIM1 is a seven-pass membrane protein associated with lysosome and endosome membranes (UniProt Q969X1 topology and subcellular annotation). In paraffin-section IHC, expect predominantly cytoplasmic staining across many tissues, including lymphoid, hematopoietic, glandular, neuronal and squamous epithelial cells (HPA tissue IHC). HPA rates the tissue IHC result Approved, while reporting low consistency between staining and RNA data and pending external verification (HPA tissue IHC).
| Cytoplasmic staining is visible in breast, colon, duodenum or gallbladder glandular cells. | These cell types have reported High staining (HPA tissue IHC). Assess the signal within the identified cells and against controls; intensity alone cannot establish antibody specificity, particularly given HPA's low staining–RNA consistency (HPA tissue IHC). |
| Discrete cytoplasmic puncta appear, with nuclei largely free of signal. | A vesicular pattern is consistent with supported ICC-IF localization (HPA subcellular), and with endosome and lysosome membrane annotation (UniProt Q969X1). Chromogenic IHC may not resolve individual vesicles; broadly cytoplasmic staining also matches the reported tissue profile (HPA tissue IHC). |
| Strong staining is confined to nuclei or appears as an unrelated tissue-wide deposit. | That compartment does not match the reported membrane and vesicle localization (UniProt Q969X1; HPA subcellular). Treat it as suspicious, then inspect counterstain, morphology and controls before assigning it to nonspecific staining (general IHC practice). |
| A cell population stains intensely where HPA reports Low staining, such as smooth muscle cells or ovarian stroma cells. | The contrast merits checking cell identification, section quality and controls (HPA tissue IHC; general IHC practice). Low means some staining may occur: this observation alone cannot prove cross-reactivity, and HPA supplies no negative cell population here (HPA tissue IHC). |
| No signal is seen in a section containing an expected High-staining population. | First confirm that the relevant cells are present: appendix lymphoid tissue and bone marrow hematopoietic cells are reported High (HPA tissue IHC). If the run controls also fail, investigate the IHC workflow before interpreting the section as biologically negative (general IHC practice). |
💡Expected TMBIM1 appearanceCall a result plausible when identifiable cells show predominantly cytoplasmic, sometimes punctate signal in an HPA High-staining population (HPA tissue IHC; HPA subcellular); isolated strong nuclear staining is a suspect result requiring controls (UniProt Q969X1; general IHC practice).
| Tissue and cell population | HPA reports cytoplasmic expression in most tissues and low RNA tissue specificity, but staining varies by cell population: several glandular populations are High, while smooth muscle and ovarian stroma cells are Low (HPA tissue IHC). Compare like cells when judging intensity. |
| Intracellular compartment | Seven transmembrane segments support a membrane-associated target (UniProt Q969X1 topology). Endosome and lysosome membranes are annotated (UniProt Q969X1); HPA supports vesicular ICC-IF localization (HPA subcellular). Neither source establishes that every paraffin-section positive cell will show resolvable puncta. |
| Strength of tissue evidence | The tissue IHC profile is Approved, with low consistency between antibody staining and RNA expression data and external verification pending (HPA tissue IHC). An IHC antibody is listed as Approved; a separate ICC antibody is Supported (HPA antibodies). Keep those application assessments distinct. |
| IF/ICC Q: What pattern is supported? | A: Vesicles are the supported main location in ICC-IF images from HaCaT, RT-4 and U2OS (HPA subcellular). Use that as a localization comparison, while interpreting paraffin-section chromogen against the separate tissue IHC profile (HPA tissue IHC). |
| Epitope and retrieval | The supplied UniProt record gives topology but no antibody epitope (UniProt Q969X1 topology). It therefore cannot predict whether a particular retrieval condition exposes the catalog antibody's epitope. Compare retrieval conditions with the antibody's IHC instructions and run controls (general IHC practice). |
| Fixation sensitivity | Target-specific fixation sensitivity is unreported in the supplied UniProt and HPA evidence. Record fixation and retrieval conditions when comparing sections (general IHC practice), without attributing a change in TMBIM1 signal to fixation from these sources. |
| Situation | Likely cause | Next action |
|---|---|---|
| Expected High-staining cells show no chromogen. | The relevant cell population may be absent from the section, or the IHC run may have failed (HPA tissue IHC; general IHC practice). | Confirm tissue morphology and the expected cell population, then review a same-run positive control and the antibody's IHC instructions before scoring the sample negative (general IHC practice). |
| Signal is weak despite a present positive-control population. | Detection or retrieval conditions may be inadequate for the assay; no TMBIM1-specific retrieval effect is established here (general IHC practice). | Check reagent activity, detection steps and documented retrieval conditions using a same-run control; change one workflow variable at a time (general IHC practice). |
| Strong nuclear staining dominates the section. | Nuclear localization conflicts with the reported membrane and vesicular locations (UniProt Q969X1; HPA subcellular); an assay artifact is possible (general IHC practice). | Inspect morphology and a no-primary control, then repeat with the antibody's validated IHC conditions if the unexpected pattern persists (general IHC practice). |
| Chromogen appears widely outside recognizable cells. | Diffuse deposition can reflect nonspecific background or detection-system activity (general IHC practice); HPA's cytoplasmic tissue profile does not support extracellular deposits as the expected pattern (HPA tissue IHC). | Check a no-primary control, washing and detection blocking steps; judge cellular signal only after background is controlled (general IHC practice). |
| A Low-staining population appears as strong as the expected High-staining cells. | Cell identification or assay background may explain the mismatch (general IHC practice); HPA's Low designation is not a negative call (HPA tissue IHC). | Recheck the cell type and compare matched sections and controls. Report the discrepancy without calling cross-reactivity solely from the HPA intensity category (HPA tissue IHC; general IHC practice). |
| IHC looks cytoplasmic, but puncta are indistinct. | HPA describes the tissue IHC profile as cytoplasmic, while vesicles are supported in ICC-IF (HPA tissue IHC; HPA subcellular); chromogenic section resolution may limit puncta assessment (general IHC practice). | Score the identifiable cells and cytoplasmic distribution against the tissue IHC reference; reserve vesicle-level interpretation for suitably resolved imaging (HPA tissue IHC; general IHC practice). |
Experiment evidence
IHC & IF images showing TMBIM1 staining
A10501-3 · IHCIHC analysis of TMBIM1 using anti-TMBIM1 antibody (A10501-3). TMBIM1 was detected in paraffin-embedded section of human gastric cancer tissu
A10501-3 · IHCIHC analysis of TMBIM1 using anti-TMBIM1 antibody (A10501-3). TMBIM1 was detected in paraffin-embedded section of human liver cancer tissue.
A10501-1 · IHCImmunohistochemical analysis of paraffin-embedded human colon cancer. 1, Tris-EDTA, pH9.0 was used for antigen retrieval. 2 Antibody was dil
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000135926-TMBIM1/tissue/cerebral+cortex#imid_3208496
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000135926-TMBIM1/tissue/colon#imid_3208430
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000135926-TMBIM1/tissue/liver#imid_3208431
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000135926-TMBIM1/tissue/kidney#imid_3208424
HPA · ICC-IF HaCaTHuman Protein Atlas immunofluorescence, HaCaT, antibody HPA070824; green = TMBIM1, blue = nucleus, red = microtubules.
HPA · ICC-IF HaCaTHuman Protein Atlas immunofluorescence, HaCaT, antibody HPA070824; green = TMBIM1, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for TMBIM1 IHC & IF
🧪Run breast first: glandular cells should stain (HPA: High in breast glandular cells). HPA detects TMBIM1 in all 45 scored tissues, so there is no supported negative tissue; use no-primary and isotype controls, and treat unstained cells on the positive slide as internal background references without assuming a particular cell type is TMBIM1-negative (HPA: no negative tissue rows).
Positive control tissue: Appendix (Lymphoid tissue, HPA High)
Negative control tissue: None in HPA: TMBIM1 is detected in all 45 scored tissues. Use a no-primary (secondary-only) and an isotype control instead.
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show TMBIM1 in HaCaT, RT-4, U2OS, with annotated localisation: Vesicles (supported) (HPA subcellular).
Technical controls: Include a no-primary, secondary-only section, a rabbit IgG control matched to the primary antibody’s clonality and concentration, and TMBIM1 knockout material or peptide competition if the cognate peptide is available (selected-SKU caption: rabbit primary). Quench endogenous peroxidase and check for endogenous biotin background when using the caption’s biotinylated secondary and SABC/DAB detection (selected-SKU caption: biotinylated secondary, SABC/DAB).
⚠️Feasibility: A target-specific fixation window or fixation effect is unreported, and the selected-SKU paraffin-section caption does not state its fixative (selected-SKU caption: fixative unreported). The caption uses heat retrieval in EDTA at pH 8.0, but does not establish that this retrieval is required (selected-SKU caption: EDTA retrieval). The supplied evidence does not establish whether frozen sections or IF are easier; ICC-IF shows supported vesicular localization, while biotin-based detection warrants a background check in the breast glandular section (HPA: vesicles supported; selected-SKU caption: biotinylated secondary and SABC/DAB).
HPA tissue IHC evidence for TMBIM1
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Approved — Low consistency between antibody staining and RNA expression data. Pending external verification.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Appendix | Lymphoid tissue | High | Protein (IHC) | HPA → |
| Bone marrow | Hematopoietic cells | High | Protein (IHC) | HPA → |
| Breast | Glandular cells | High | Protein (IHC) | HPA → |
| Cerebral cortex | Neuronal cells | High | Protein (IHC) | HPA → |
| Cervix | Squamous epithelial cells | High | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| None in HPA: TMBIM1 is detected in all 45 scored tissues. Use a no-primary (secondary-only) and an isotype control instead. | ||||
Section 3
Advanced TMBIM1 IHC Tips
Troubleshoot TMBIM1 staining in paraffin sections by checking retrieval, compartment, controls, and scoring alongside the documented chromogenic IHC workflow.
Which antigen retrieval should I try first for weak TMBIM1 staining?
Begin heat-mediated retrieval in EDTA at pH 8.0 for paraffin-section chromogenic IHC (datasheet A10501-3). The documented tissue image used that retrieval before incubation with 2 µg/ml catalog antibody overnight at 4°C (caption A10501-3). If staining is weak, compare retrieved and unretrieved serial sections while keeping antibody concentration and detection conditions matched (standard IHC practice). Check tissue preservation and include a positive control before increasing retrieval intensity, since tissue damage can complicate interpretation (standard IHC practice). Record heating and cooling conditions for each run so changes in vesicular or cytoplasmic staining can be assessed consistently (HPA subcellular; standard IHC practice).
Could fixation explain inconsistent TMBIM1 staining between paraffin blocks?
Target-specific fixation sensitivity is unknown, and the selected paraffin-section caption does not state its fixative (caption A10501-3). Record the fixative, fixation duration, processing history, and section age for each block before comparing staining intensity (standard IHC practice). Run sections from the blocks together with the same EDTA pH 8.0 retrieval and antibody conditions to limit technical variation (datasheet A10501-3; standard IHC practice). Include a consistently processed positive-control section and assess morphology alongside signal, because damaged tissue makes staining difficult to interpret (standard IHC practice). Do not assign a block-to-block difference to TMBIM1 biology until the processing variables and controls have been reviewed (standard IHC practice).
What staining pattern should I expect in a TMBIM1-positive section?
Look for cytoplasmic staining with a possible punctate pattern: tissue IHC is described as cytoplasmic, while supported cell imaging places TMBIM1 in vesicles (HPA tissue IHC; HPA subcellular). Endosome and lysosome membranes are annotated locations, consistent with intracellular vesicular signal (UniProt Q969X1 subcellular). Assess staining within morphologically identified cells rather than treating diffuse extracellular DAB as a cellular pattern (standard IHC practice). A predominantly nuclear or extracellular pattern deserves a specificity check against positive-control tissue and a no-primary control (UniProt Q969X1 subcellular; standard IHC practice). Chromogenic resolution may merge small puncta into broader cytoplasmic staining, so compare serial sections under consistent imaging conditions (standard IHC practice).
How can epitope placement affect TMBIM1 detection after retrieval?
TMBIM1 is annotated as a 311-amino-acid chain with 7 transmembrane segments, but the supplied antibody evidence does not map its epitope (UniProt Q969X1 topology; caption A10501-3). Therefore, do not assume that a negative paraffin section rules out the protein solely because retrieval was performed (standard IHC interpretation). Annotated phosphoserines at positions 81 and 83 could matter only if an antibody recognizes a relevant epitope; no such specificity is supplied (UniProt Q969X1 modified residues; caption A10501-3). The record lists 0 annotated isoforms, which does not establish that every specimen exposes the antibody epitope equally (UniProt Q969X1 isoforms; standard IHC interpretation). Compare controls using the documented EDTA pH 8.0 retrieval before attributing discordance to epitope accessibility (datasheet A10501-3; standard IHC practice).
How should I use IF to investigate ambiguous chromogenic TMBIM1 staining?
Use IF/ICC as a secondary localisation check, while keeping the documented paraffin-section chromogenic IHC result as the starting point (caption A10501-3; standard IHC practice). Multiplex TMBIM1 with a validated marker for the cell population being assessed, such as glandular cells in a relevant section, to test cell assignment (HPA tissue IHC; standard IF practice). Choose a fluorophore channel after inspecting tissue autofluorescence, and include single-label controls to distinguish signal from bleed-through (standard IF practice). Set permeabilisation according to the mapped epitope’s side of the membrane; that side is not supplied for this antibody (UniProt Q969X1 topology; caption A10501-3; standard IF practice). Compare any puncta with the supported vesicular localisation without treating fluorescence alone as proof of antibody specificity (HPA subcellular; standard IF practice).
How do I distinguish TMBIM1 signal from chromogenic background?
Start by comparing the stained section with a no-primary control processed through the same secondary antibody and DAB detection steps (standard IHC practice). The documented workflow used 10% goat serum, a biotinylated secondary antibody, a streptavidin-biotin complex, and DAB (caption A10501-3). Include a peroxidase-blocking step and assess possible endogenous biotin contribution when troubleshooting background in that detection format (standard IHC practice; caption A10501-3). Examine tissue edges, folds, and necrotic areas separately from intact cells, because deposits there can mislead scoring (standard IHC practice). Retain a positive-control section so reducing background does not inadvertently remove the expected cytoplasmic signal (HPA tissue IHC; standard IHC practice).
What is a defensible way to quantify TMBIM1 IHC across sections? ⚠ ANSWER MARKED FOR VERIFICATION
Define the cell population and viable tissue region before scoring, then apply the same thresholds and imaging settings across sections (standard IHC practice). Report the percentage of positive cells and an intensity-based H-score on its usual 0–300 scale when cellular staining can be resolved (standard IHC practice). For discrete positive cells, density per mm² of viable tissue can supplement the percentage; normalise counts to the assessed area or eligible cell population (standard IHC practice). Score cytoplasmic staining consistently with the reported tissue pattern, and document whether punctate signal was included (HPA tissue IHC; HPA subcellular; standard IHC practice). Interpret between-tissue differences cautiously because HPA reports low consistency between antibody staining and RNA expression (HPA tissue IHC).
What would make a positive TMBIM1 stain convincing rather than artefactual?
A convincing result has cellular cytoplasmic staining in intact tissue, potentially with vesicular puncta, and exceeds the matched no-primary control (HPA tissue IHC; HPA subcellular; standard IHC practice). Check cell identity: HPA reports high staining in several populations, including colon glandular cells and bone-marrow hematopoietic cells, but also flags limited agreement with RNA data (HPA tissue IHC). Predominantly nuclear or extracellular staining conflicts with the annotated endosome and lysosome membrane locations and needs further validation (UniProt Q969X1 subcellular; standard IHC practice). Discount signal confined to cut edges or necrosis, and investigate DAB signal attributable to endogenous peroxidase (standard IHC practice). Confirm that the positive control stains as expected under the documented EDTA pH 8.0 retrieval before interpreting a negative specimen (datasheet A10501-3; standard IHC practice).
Boster reagents
Best TMBIM1 / Protein lifeguard 3 IHC Antibodies
Both antibodies have human paraffin-section IHC images (catalog image captions). Both list human, mouse, and rat reactivity; only A10501-1 lists IF (catalog applications/reactivity).
Real IHC data
Anti-TMBIM1 Antibody ®
Cat # A10501-3
Real IHC data
Anti-RECS1 TMBIM1 Antibody
Cat # A10501-1
A10501-3 will render with a human gastric cancer paraffin-section IHC image; its catalog also shows human liver cancer and placenta IHC images (A10501-3 image captions). A10501-1 will render with a human colon cancer paraffin-section IHC image and lists IF as an application, with no IF image supplied (A10501-1 image caption; catalog applications/images).
Which to pick: For tissue IHC, choose A10501-3 when its human gastric cancer, liver cancer, or placenta examples match the planned sample: its paraffin-section captions use EDTA retrieval at pH 8.0, and the fixative is unreported (A10501-3 image captions). For IF, choose A10501-1 because IF is listed; ICC is unreported, and its own human colon cancer paraffin-section IHC caption uses Tris-EDTA retrieval at pH 9.0 with the fixative unreported (A10501-1 catalog applications; A10501-1 image caption). For mouse or rat work, either SKU lists reactivity, but the supplied IHC images are human only and clonality is unreported for both (catalog reactivity, image captions, and clone fields).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry Q969X1 (LFG3_HUMAN, Protein lifeguard 3).
- Human Protein Atlas. TMBIM1 tissue IHC expression (reliability: Approved).
- Human Protein Atlas. TMBIM1 subcellular location (ICC-IF): Localized to vesicles..
- Human Protein Atlas. TMBIM1 antibody validation summary (2 antibodies).
- Transmembrane BAX inhibitor motif containing 1 inhibition of lysosomal degradation of TGF-β receptor 1 suppresses cellular senescence and hepatocarcinogenesis. The Journal of biological chemistry 2025 — PMC12702014.
- Loss of Epithelial Homeostasis Driven by TMBIM1 Depletion via E-Cadherin Junction Disassembly. International journal of molecular sciences 2026 — PMC12842013.
- TMBIM1 promotes proliferation and attenuates apoptosis in glioblastoma cells by targeting the p38 MAPK signalling pathway. Translational oncology 2022 — PMC8920937.
- Th17-related genes PGAP1 and TMBIM1 serve as potential diagnostic and predictive biomarkers in systemic sclerosis: bioinformatic identification and murine model validation. Clinical rheumatology 2026 — PMC12923484.
- PubMed PMID:14702039 — UniProt-cited evidence.
- PubMed PMID:15498874 — UniProt-cited evidence.
- PubMed PMID:16303743 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for TMBIM1 (Protein lifeguard 3). Expected localisation Cytoplasmic tissue staining (HPA tissue IHC); lysosome and endosome membranes (UniProt). Antigen retrieval: EDTA pH 8.0 HIER, heat-mediated (datasheet A10501-3). Validated IHC antibody: A10501-3 at 2μg/ml (the product's own IHC validation image is shown). Controls (HPA): positive Appendix (Lymphoid tissue); negative None in HPA (detected in all 45 tissues); use no-primary + isotype controls. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded human gastric cancer tissue; fixative not specified (datasheet A10501-3); 2. Fixation: Image fixative and duration unreported (datasheet A10501-3); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: EDTA pH 8.0 (datasheet A10501-3); 20 min, 95–100 °C (standard); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% goat serum (datasheet A10501-3); 8. Primary antibody: Rabbit anti-TMBIM1, 2μg/ml (datasheet A10501-3); 9. Primary incubation: Overnight at 4 °C (datasheet A10501-3). Watch for: Fixation: Keep fixation consistent across sections (standard IHC practice; not target-specific); Caveat: Antibody staining and RNA show low consistency (HPA tissue IHC); Isoform / epitope: No isoforms or cleavage annotated; epitope side may affect access (UniProt); Regulation: Expression regulation is not annotated (UniProt). Evidence: UniProt Q969X1, HPA tissue IHC · Approved, HPA ICC-IF · vesicles., Datasheet A10501-3, PMC12702014, PMC12842013. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/TMBIM1/immunohistochemistry-ihc-guide.